|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Peters GJ, Backus HH, Freemantle S, van
Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J,
Calvert AH, Marsh S, et al: Induction of thymidylate synthase as a
5-fluorouracil resistance mechanism. Biochim Biophys Acta.
1587:194–205. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guinney J, Dienstmann R, Wang X, de
Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda
G, Angelino P, et al: The consensus molecular subtypes of
colorectal cancer. Nat Med. 21:1350–1356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang Z, Zhou C, Chang Y, Zhang Z, Hu Y,
Zhang F, Lu Y, Zheng L, Zhang W, Li X, et al: Long non-coding RNA
CASC11 interacts with hnRNP-K and activates the WNT/β-catenin
pathway to promote growth and metastasis in colorectal cancer.
Cancer Lett. 376:62–73. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zheng K, Zhou X, Yu J, Li Q, Wang H, Li M,
Shao Z, Zhang F, Luo Y, Shen Z, et al: Epigenetic silencing of
miR-490-3p promotes development of an aggressive colorectal cancer
phenotype through activation of the Wnt/β-catenin signaling
pathway. Cancer Lett. 376:178–187. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gao Y, Liu Z, Zhang X, He J, Pan Y, Hao F,
Xie L, Li Q, Qiu X and Wang E: Inhibition of cytoplasmic GSK-3β
increases cisplatin resistance through activation of Wnt/β-catenin
signaling in A549/DDP cells. Cancer Lett. 336:231–239. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vermeulen L, De Sousa E, Melo F, van der
Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M,
Merz C, Rodermond H, et al: Wnt activity defines colon cancer stem
cells and is regulated by the microenvironment. Nat Cell Biol.
12:468–476. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Morin PJ, Sparks AB, Korinek V, Barker N,
Clevers H, Vogelstein B and Kinzler KW: Activation of
beta-catenin-Tcf signaling in colon cancer by mutations in
beta-catenin or APC. Science. 275:1787–1790. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kimelman D and Xu W: beta-catenin
destruction complex: Insights and questions from a structural
perspective. Oncogene. 25:7482–7491. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Prunier C, Hocevar BA and Howe PH: Wnt
signaling: Physiology and pathology. Growth Factors. 22:141–150.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cui J, Jiang W, Wang S, Wang L and Xie K:
Role of Wnt/β-catenin signaling in drug resistance of pancreatic
cancer. Curr Pharm Des. 18:2464–2471. 2012. View Article : Google Scholar
|
|
12
|
Wu X, Luo F, Li J, Zhong X and Liu K:
Tankyrase 1 inhibitior XAV939 increases chemosensitivity in colon
cancer cell lines via inhibition of the Wnt signaling pathway. Int
J Oncol. 48:1333–1340. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Woodgett JR: Molecular cloning and
expression of glycogen synthase kinase-3/factor A. EMBO J.
9:2431–2438. 1990.PubMed/NCBI
|
|
14
|
Embi N, Rylatt DB and Cohen P: Glycogen
synthase kinase-3 from rabbit skeletal muscle. Separation from
cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J
Biochem. 107:519–527. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lucas JJ, Hernández F, Gómez-Ramos P,
Morán MA, Hen R and Avila J: Decreased nuclear beta-catenin, tau
hyperphosphorylation and neurodegeneration in GSK-3beta conditional
transgenic mice. EMBO J. 20:27–39. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Takahashi-Yanaga F and Sasaguri T:
GSK-3beta regulates cyclin D1 expression: A new target for
chemotherapy. Cell Signal. 20:581–589. 2008. View Article : Google Scholar
|
|
17
|
Grassilli E, Narloch R, Federzoni E,
Ianzano L, Pisano F, Giovannoni R, Romano G, Masiero L, Leone BE,
Bonin S, et al: Inhibition of GSK3B bypass drug resistance of
p53-null colon carcinomas by enabling necroptosis in response to
chemotherapy. Clin Cancer Res. 19:3820–3831. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Z, Smith KS, Murphy M, Piloto O,
Somervaille TC and Cleary ML: Glycogen synthase kinase 3 in MLL
leukaemia maintenance and targeted therapy. Nature. 455:1205–1209.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Forde JE and Dale TC: Glycogen synthase
kinase 3: A key regulator of cellular fate. Cell Mol Life Sci.
64:1930–1944. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sato N, Meijer L, Skaltsounis L, Greengard
P and Brivanlou AH: Maintenance of pluripotency in human and mouse
embryonic stem cells through activation of Wnt signaling by a
pharmacological GSK-3-specific inhibitor. Nat Med. 10:55–63. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu L, Nam S, Tian Y, Yang F, Wu J, Wang
Y, Scuto A, Polychronopoulos P, Magiatis P, Skaltsounis L, et al:
6-Bromoindirubin-3′-oxime inhibits JAK/STAT3 signaling and induces
apoptosis of human melanoma cells. Cancer Res. 71:3972–3979. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu AS and Zhao L: Effects of the GSK-3β
inhibitor (2Z,3E)-6-bromoindirubin-3′-oxime upon ovarian cancer
cells. Tumour Biol. 37:4857–4864. 2016. View Article : Google Scholar
|
|
23
|
Eslaminejad MB, Salami F, Mehranjani MS,
Abnoosi M and Eftekhari-yazdi P: BIO treatment enhances rat
marrow-derived mesenchymal stem cell in vitro proliferation and
viability. Physiol Pharmacol. 13:121–126. 2009.
|
|
24
|
Tseng AS, Engel FB and Keating MT: The
GSK-3 inhibitor BIO promotes proliferation in mammalian
cardiomyocytes. Chem Biol. 13:957–963. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lu L, Zhang Q, Wu K, Chen X, Zheng Y, Zhu
C and Wu J: Hepatitis C virus NS3 protein enhances cancer cell
invasion by activating matrix metalloproteinase-9 and
cyclooxygenase-2 through ERK/p38/NF-κB signal cascade. Cancer Lett.
356:470–478. 2015. View Article : Google Scholar
|
|
26
|
Che YL, Luo SJ, Li G, Cheng M, Gao YM, Li
XM, Dai JM, He H, Wang J, Peng HJ, et al: The C3G/Rap1 pathway
promotes secretion of MMP-2 and MMP-9 and is involved in serous
ovarian cancer metastasis. Cancer Lett. 359:241–249. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Batlle E, Sancho E, Francí C, Domínguez D,
Monfar M, Baulida J and García De Herreros A: The transcription
factor snail is a repressor of E-cadherin gene expression in
epithelial tumour cells. Nat Cell Biol. 2:84–89. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou BP, Deng J, Xia W, Xu J, Li YM,
Gunduz M and Hung MC: Dual regulation of Snail by
GSK-3beta-mediated phosphorylation in control of
epithelial-mesenchymal transition. Nat Cell Biol. 6:931–940. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Petitclerc E, Deschesnes RG, Côté MF,
Marquis C, Janvier R, Lacroix J, Miot-Noirault E, Legault J,
Mounetou E, Madelmont JC, et al: Antiangiogenic and antitumoral
activity of phenyl-3-(2-chloroethyl)ureas: A class of soft
alkylating agents disrupting microtubules that are unaffected by
cell adhesion-mediated drug resistance. Cancer Res. 64:4654–4663.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shain KH and Dalton WS: Cell adhesion is a
key determinant in de novo multidrug resistance (MDR): New targets
for the prevention of acquired MDR. Mol Cancer Ther. 1:69–78.
2001.
|
|
31
|
Damiano JS, Cress AE, Hazlehurst LA, Shtil
AA and Dalton WS: Cell adhesion mediated drug resistance (CAM-DR):
Role of integrins and resistance to apoptosis in human myeloma cell
lines. Blood. 93:1658–1667. 1999.PubMed/NCBI
|
|
32
|
Liu KP, Luo F, Xie SM, Tang LJ, Chen MX,
Wu XF, Zhong XY and Zhao T: Glycogen synthase kinase 3β inhibitor
(2′Z,3′E)-6-Bromo-indirubin-3′-oxime enhances drug resistance to
5-fluorouracil chemotherapy in colon cancer cells. Chin J Cancer
Res. 24:116–123. 2012. View Article : Google Scholar
|
|
33
|
Yang HZ, Ma Y, Zhou Y, Xu LM, Chen XJ,
Ding WB and Zou HB: Autophagy contributes to the enrichment and
survival of colorectal cancer stem cells under oxaliplatin
treatment. Cancer Lett. 361:128–136. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
De Angelis ML, Zeuner A, Policicchio E,
Russo G, Bruselles A, Signore M, Vitale S, De Luca G, Pilozzi E,
Boe A, et al: Cancer stem cell-based models of colorectal cancer
reveal molecular determinants of therapy resistance. Stem Cells
Transl Med. 5:511–523. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
McCubrey JA, Steelman LS, Abrams SL,
Misaghian N, Chappell WH, Basecke J, Nicoletti F, Libra M, Ligresti
G, Stivala F, et al: Targeting the cancer initiating cell: The
ultimate target for cancer therapy. Curr Pharm Des. 18:1784–1795.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nakanishi Y, Seno H, Fukuoka A, Ueo T,
Yamaga Y, Maruno T, Nakanishi N, Kanda K, Komekado H, Kawada M, et
al: Dclk1 distinguishes between tumor and normal stem cells in the
intestine. Nat Genet. 45:98–103. 2013. View Article : Google Scholar
|
|
37
|
Imrich S, Hachmeister M and Gires O: EpCAM
and its potential role in tumor-initiating cells. Cell Adhes Migr.
6:30–38. 2012. View Article : Google Scholar
|
|
38
|
Merlos-Suárez A, Barriga FM, Jung P,
Iglesias M, Céspedes MV, Rossell D, Sevillano M, Hernando-Momblona
X, da Silva-Diz V, Muñoz P, et al: The intestinal stem cell
signature identifies colorectal cancer stem cells and predicts
disease relapse. Cell Stem Cell. 8:511–524. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Elsaba TM, Martinez-Pomares L, Robins AR,
Crook S, Seth R, Jackson D, McCart A, Silver AR, Tomlinson IP and
Ilyas M: The stem cell marker CD133 associates with enhanced colony
formation and cell motility in colorectal cancer. PLoS One.
5:e107142010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Leibovitz A, Stinson JC, McCombs WB III,
McCoy CE, Mazur KC and Mabry ND: Classification of human colorectal
adenocarcinoma cell lines. Cancer Res. 36:4562–4569.
1976.PubMed/NCBI
|
|
41
|
Luo F, Li J, Wu S, Wu X, Chen M, Zhong X
and Liu K: Comparative profiling between primary colorectal
carcinomas and metastases identifies heterogeneity on drug
resistance. Oncotarget. 7:63937–63949. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jiang H, Guo W, Liang X and Rao Y: Both
the establishment and the maintenance of neuronal polarity require
active mechanisms: Critical roles of GSK-3beta and its upstream
regulators. Cell. 120:123–135. 2005.PubMed/NCBI
|
|
43
|
Doble BW and Woodgett JR: GSK-3: Tricks of
the trade for a multi-tasking kinase. J Cell Sci. 116:1175–1186.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lin CL, Wang JY, Huang YT, Kuo YH,
Surendran K and Wang FS: Wnt/beta-catenin signaling modulates
survival of high glucose-stressed mesangial cells. J Am Soc
Nephrol. 17:2812–2820. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jain S, Ghanghas P, Rana C and Sanyal SN:
Role of GSK-3β in regulation of canonical Wnt/β-catenin signaling
and PI3-K/Akt oncogenic pathway in colon cancer. Cancer Invest.
35:473–483. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ikeda S, Kishida S, Yamamoto H, Murai H,
Koyama S and Kikuchi A: Axin, a negative regulator of the Wnt
signaling pathway, forms a complex with GSK-3beta and beta-catenin
and promotes GSK-3beta-dependent phosphorylation of beta-catenin.
EMBO J. 17:1371–1384. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang WJ, Wu MY, Shen M, Zhi Q, Liu ZY,
Gong FR, Tao M and Li W: Cantharidin and norcantharidin impair
stemness of pancreatic cancer cells by repressing the β-catenin
pathway and strengthen the cytotoxicity of gemcitabine and
erlotinib. Int J Oncol. 47:1912–1922. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Todaro M, Francipane MG, Medema JP and
Stassi G: Colon cancer stem cells: Promise of targeted therapy.
Gastroenterology. 138:2151–2162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hennessy BT, Smith DL, Ram PT, Lu Y and
Mills GB: Exploiting the PI3K/AKT pathway for cancer drug
discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Buss H, Dörrie A, Schmitz ML, Frank R,
Livingstone M, Resch K and Kracht M: Phosphorylation of serine 468
by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J
Biol Chem. 279:49571–49574. 2004. View Article : Google Scholar : PubMed/NCBI
|
